LivaNova PLC (NASDAQ:LIVN) Given Consensus Rating of "Buy" by Analysts

LivaNova PLC (NASDAQ:LIVN - Get Free Report) has been assigned an average recommendation of "Buy" from the eight analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $59.29.

LIVN has been the topic of several research analyst reports. Barclays decreased their price target on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 8th. Needham & Company LLC restated a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research report on Tuesday, May 13th. Mizuho decreased their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. Robert W. Baird raised their price target on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen lowered shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th.

Institutional Trading of LivaNova

Several institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of LivaNova by 13.5% during the 1st quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company's stock valued at $104,755,000 after acquiring an additional 316,993 shares in the last quarter. Capital Research Global Investors boosted its position in shares of LivaNova by 19.1% during the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock valued at $74,690,000 after acquiring an additional 258,730 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of LivaNova by 111.7% during the 1st quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company's stock valued at $60,809,000 after acquiring an additional 829,115 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of LivaNova by 8.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company's stock valued at $60,710,000 after acquiring an additional 107,693 shares in the last quarter. Finally, Redmile Group LLC boosted its position in shares of LivaNova by 19.3% during the 4th quarter. Redmile Group LLC now owns 1,043,539 shares of the company's stock valued at $48,326,000 after acquiring an additional 168,500 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Stock Performance

NASDAQ:LIVN opened at $45.51 on Friday. LivaNova has a 1 year low of $32.48 and a 1 year high of $57.35. The firm's fifty day simple moving average is $41.63 and its 200 day simple moving average is $43.67. The company has a current ratio of 1.58, a quick ratio of 1.37 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $2.48 billion, a PE ratio of -11.13 and a beta of 0.90.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.